CLL Society was established on the four pillars of education, advocacy, support, and research to equitably meet the unmet needs of the CLL/SLL patient and caregiver community.

For us, advocacy has meant working publicly and behind the scenes to support policies and causes important to those whose lives are touched by chronic lymphocytic leukemia and small lymphocytic lymphoma.

Areas of our advocacy include, but are by no means limited to:

  • Equitable access to care
  • Funding for CLL/SLL research
  • Recognition of the unique needs of the immunocompromised


CLL Society Organizes Joint Effort Urging Government Agencies to Focus on Continued COVID-19 for the Immunocompromised

In light of the FDA’s announcements regarding the discontinuation of Emergency Use Authorization for both Evusheld and Bebtelovimab, CLL Society and eight other patient advocacy organizations sent a letter to federal officials requesting them to immediately undertake thirteen specific actions that would help protect the estimated seven million Americans who are immunocompromised against COVID-19.
Read more.

CLL Society Sends a Comment Letter to the Centers for Medicare and Medicaid Services (CMS)

CLL Society voiced strong support of the CMS proposal to continue the existing policy to pay for COVID-19 monoclonal antibodies and their administration (such as Evusheld) under the Part B vaccine benefit.

Read more.